ELTX - Company ID 0001601485
The table below shows Elicio Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | $2.30M | $28.31M | $2.88M |
| Cost of revenue | - | - | - | $0.00 | $433.00K | $1.19M |
| Gross profit | - | - | - | - | - | - |
| R&D | $24.90M | $33.66M | $23.85M | $18.10M | $48.70M | $38.98M |
| SG&A |
Elicio Therapeutics, Inc. reported annual revenue of $2.30M for fiscal year 2022. That is down 91.9% from $28.31M in fiscal 2021. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $12.81M |
| $11.33M |
| $11.90M |
| $5.63M |
| $18.49M |
| $17.99M |
| Operating income | -$37.71M | -$44.99M | -$35.74M | -$23.73M | -$39.31M | -$55.27M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$39.57M | -$51.90M | -$35.20M | -$28.21M | -$54.57M | -$80.11M |
| EPS (diluted) | -$2.58 | -$4.25 | -$6.96 | -$89.27 | -$1.93 | -$5.43 |